Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma

Marie R. Webster(The Wistar Institute), Ashani T. Weeraratna(Johns Hopkins University), Ravi K. Amaravadi(University of Pennsylvania), Tara C. Mitchell(Hospital of the University of Pennsylvania), Lynn M. Schuchter(Eastern Cooperative Oncology Group), Andrew V. Kossenkov(The Wistar Institute), Gretchen M. Alicea(The Wistar Institute), Curtis H. Kugel(The Wistar Institute), Meenhard Herlyn(The Wistar Institute), Min Xiao(Harbin Medical University), Abibatou Ndoye(The Wistar Institute), Alexander A. Valiga(Thomas Jefferson University Hospital), Stephen M. Douglass(Johns Hopkins University), Giorgos C. Karakousis(Hospital of the University of Pennsylvania), Xiaowei Xu(Southwest University of Science and Technology), Mitchell E. Fane(The Wistar Institute), Brett L. Ecker(Rutgers, The State University of New Jersey), Wei Xu(Obstetrics and Gynecology Hospital of Fudan University), Keerthana Gnanapradeepan(C4 Therapeutics (United States)), Amanpreet Kaur(The Wistar Institute), Cathy Zheng(University of Pennsylvania), Ying‐Jie Wang(Zhejiang University), Vito W. Rebecca(Johns Hopkins University), Maureen E. Murphy(The Wistar Institute), Qin Liu(University of Science and Technology of China), Jessica Palmer(The Wistar Institute), Xiangfan Yin(The Wistar Institute), Jessicamarie Morris(The Wistar Institute), Subhasree Basu(The Wistar Institute), Hong Wu(Beijing Forestry University), Gloria E. Marino(The Wistar Institute), Filipe V. Almeida(The Wistar Institute)

Molecular Cell

February 1, 2020

Cited by 14

Related Papers

|The EMBO Journal|2021|1.6k

|Cell|2018|1.5k

|Somatic Cell and Molecular Genetics|1979|1.4k

|Cancer Research|2005|1.3k

|Journal of Clinical Investigation|2007|1.1k